621 |
Charakterisierung und Identifizierung von immundominanten Bereichen der L3-Chitinase von Onchocerca volvulusDrabner, Birgit 08 May 2000 (has links)
Da Filarieninfektionen noch immer chemotherapeutisch schwer bekämpfbar sind, ist die Aufklärung von potentiell protektiven Molekülen, die zur Impfstoffentwicklung von Nutzen sein könnten, von Bedeutung. Ein vielversprechendes Antigen stellt in diesem Zusammenhang die Chitinase von infektiösen Drittlarven von Onchocerca volvulus dar. In dieser Arbeit sollte deshalb dieses Protein immunologisch charakterisiert und immundominante Bereiche identifiziert werden. Dazu wurde die cDNA des gesamten Proteins (OvL3-Chitinase) und die cDNA der Domäne, die für die Chitin-Bindung verantwortlich ist (OvL3-CBD), in einen Expressionsvektor kloniert, in E. coli exprimiert und aufgereinigt. Die aufgereinigte OvL3-Chitinase zeigte enzymatische Aktivität. Die OvL3-Chitinase und die OvL3-CBD wurden in Immunisierungsstudien im Tiermodel der Nagetierfilarie A. viteae und M. unguiculatus eingesetzt. Während die Immunisierung mit OvL3-CBD mit dem Adjuvans Alum zu keiner Reduzierung der Adultwurmlast führte, war nach Gabe der OvL3-Chitinase die Anzahl der Adultwürmer um 40 % bzw. um 17,7% reduziert. Zusätzlich wurde die OvL3-Chitinase allein und in Kombination mit zwei verschiedenen Adjuvantien (STP und Alum) in Immunisierungsstudien von BALB/c-Mäusen eingesetzt, deren Immunantworten anschließend charakterisiert wurden. Durch diese Versuche konnte gezeigt werden, daß die Chitinase ohne zusätzliche Gabe eines Adjuvans unter den getesteten Bedingungen eine TH2-Immunantwort induziert. Dies wurde durch die Anwesenheit von Antikörpern der Subklasse IgG1 deutlich. Außerdem waren Milzzellen dieser Mäuse nicht in der Lage, nach Restimulation mit Chitinase mit Proliferation zu reagieren. Durch den Einsatz der Adjuvantien STP und Alum konnte eine Polarisation der Immunantworten erfolgen. Während die Immunisierung mit Chitinase und Alum zur deutlichen Bildung von IgG1-Antikörpern und zu einer leichten Erhöhung der Antikörper IgG2a und IgG2b führte, konnte nach Immunisierung mit Chitinase und STP neben Antikörpern der Subklasse IgG1 deutliche erhöhte OD-Werte von IgG2a und IgG2b gemessen werden. In beiden Gruppen reagierten Milzzellen nach Restimulation mit Chitinase, wobei die Proliferationswerte der STP/Chitinase-Gruppe über denen der Alum/Chitinase-Gruppe lagen. Durch den Einsatz von Salmonellen, die Chitinase exprimierten, konnten die T-Zell-Antworten verstärkt werden. Es konnten jedoch keine antigen-spezifischen Antikörper gefunden werden. Mit Hilfe von drei verschiedenen T-Zell-Algorithmen (Algorithmus nach Rothbard und Taylor, nach Humphreys und die MHC-II-Bindungs-Motive nach Rammensee) wurden T-Zell-Epitope innerhalb der OvL3-Chitinase identifiziert. Alle vorhergesagten Epitope wurden als synthetische Peptide hergestellt und in T-Zell-Proliferationstests eingesetzt. Hierzu wurden Milzzellen von Mäusen verwendet, die dreimal mit rekombinanter Chitinase und dem Adjuvans STP immunisiert worden waren. Um möglichst viele T-Zell-Epitope innerhalb der Chitinase zu ermitteln, wurden überlappende Peptide (Pepscan), die die Gesamtheit der Chitinase umfaßten, in T-Zell-Tests eingesetzt. Die verwendeten Algorithmen wurde auf ihre Sensitivität und Spezifität überprüft, indem die vorhergesagten Epitope mit den ermittelten T-Zell-Epitopen des Pepscans verglichen wurden. Dabei konnte der Algorithmus von Rammensee den besten Index an Sensitivität (0,47) und Spezifität (0,7) erzielen. Eine Kombination der Algorithmen ergab, daß die Verknüpfung des Algorithmus nach Rothbard und Taylor mit den MHC-Bindungs-Motiven nach Rammensee die Sensitivität auf 0,67 erhöhen konnte, doch die Spezifität sank durch die hohe Anzahl der vorhergesagten Epitope auf 0,33. Die Anwendung der Algorithmen auf die Sequenz der OvL3-Chitinase führte zu der Identifizierung von fünf Bereichen, die von allen Algorithmen vorhergesagt wurden, und von denen vier in T-Zell-Proliferationstests deutliche Proliferationswerte erzielten. Zusätzlich wurde die OvL3-Chitinase und die OvL3-CBD in Kamerun hinsichtlich ihrer Fähigkeit getestet, PBMC von Onchozerkose-Patienten zu restimulieren, die aus einem hyperendemischen Onchozerkose-Gebiet stammten. Diese Untersuchungen bestätigten die Ergebnisse aus den Immunisierungsstudien mit BALB/c-Mäusen, in denen Chitinase eine TH2-Immunantwort hervorrief. Die PBMC der Onchozerkose-Patienten zeigten nur eine sehr geringe Proliferation nach Stimulation mit OvL3-Chitinase und OvL3-CBD. Begleitet wurde diese Proliferation von Ausschüttung typischer TH2-Zytokine wie IL-10 (Chitinase) bzw. IL-4, IL-5 und IL-10 (CBD). Die Untersuchung der Antikörperantworten der Onchozerkose-Patienten zeigte, daß bei 77% der untersuchten Patienten IgG4-Antikörper gegen die Chitinase und bei 20% gegen die OvL3-CBD im Serum nachgewiesen werden konnten. / Chemotherapeutic treatment of filarial infections has rendered difficult and still insufficient. Therefore, the identification of potentially protective molecules which can be used for vaccine development is desirable. The chitinase of larvae stage three of Onchocerca volvulus constitutes a promising antigen. Immunological characterization of this protein and the identification of immunodominat regions was performed in this study. The complete sequence (OvL3-chitinase) and the C-terminal end responsible for the binding of chitin (OvL3-CBD) were cloned in an expression vector, overexpressed in E. coli and subsequently purified. Recombinant chitinase was enzymatically active. The OvL3-chitinase and the OvL3-CBD were used for immunization studies using the rodent filaria A. viteae in the animal model M. unguiculatus. No decreased number of adult worms was observed after immunization with OvL3-CBD in the present of Alum as adjuvans, while chitinase together with STP resulted in the reduction the worm burden to 40 % (first trial) and to 17,7 % (second trial). Additional immunization studies using BALB/c-mice were performed with OvL3-chitinase in the absence or the presence of two different adjuvans. Spleen cells isolated from mice immunized with chitinase in the absence of adjuvans were devoid of proliferative capacity after in vitro antigenic restimulation. Antigen-specific IgG1 antibodies were the only subtype detectable in sera from mice. These results suggested that a Th2 response was induced after immunization with chitinase under these conditions. Including STP or Alum in the immunization protocol a polarization of the obtained immune response was found. Immunization with chitinase together with Alum elicited strong IgG1 response followed by slightly increase of IgG2a and IgG2b. Co-administration of chitinase and STP evoked increased IgG2a and IgG2b antibodies in addition to the observed IgG1 response. Good proliferative responses were observed for spleen cells from mice immunized with chitinase in the present of both adjuvans after in vitro restimulation with chitinase. Furthermore stronger T-cell reactivity was found in the group immunized with chitinase/STP. Also chitinase was expressed in Salmonella and oral immunization of mice with this construct enforced the T-cell reactivity, however antigen specific antibodies were undetectable. To further characterize T cell reactivity against OvL3-chitinase T cell epitopes using the Rothbard and Taylor algorithm (1988), Humphreys prediction and the MHC-II-binding motifs from Rammmensee (1995) were identified. All predicted epitopes were synthesized and tested in T-cell proliferation assays. Additional synthetic L3-chitinase-derived overlapping peptides were also used in T-cell proliferation assays. The sensitivity and specificity of the algorithms was evaluated by comparing the predicted epitopes with the epitopes determined by overlapping peptides. Using this approach, prediction based on MHC-II-binding motifs showed the highest sensitivity (0,47) and specificity (0,7). A further increase of the predictive power was obtained by a combining MHC-II-binding motifs and Rothbard and Taylor algorithm, resulting in increased sensitivity (0,67) but lower specificity (0,33). Five immunodominant regions were identified by all algorithm and four of them were confirmed as T-cell epitopes in T-cell assays. PBMCs isolated from patients affected with Onchocerca volvulus from Cameroon were also tested for their reactivity against OvL3-chitinase and the OvL3 CBD in T-cell proliferation assays. After in vitro restimulation with OvL3-chitinase and CBD only marginal T-cell response was observed accompanied by release of Th2-like cytokines such as IL-10 when stimulated with chitinase and IL-4, IL-5 and IL-10 when stimulated with CBD. Strong antibody responses of the IgG4 isotype were detected in the serum of 77% of the patients against chitinase and only in 20% of the patients against CBD.
|
622 |
Selective ablation of thymic and peripheral Foxp3+ regulatory T cell developmentYilmazer, Acelya, Zevla, Dimitra Maria, Malmkvist, Rikke, Bello Rodríguez, Carlos Alejandro, Undurraga, Pablo, Kirgin, Emre, Boernert, Marie, Voehringer, David, Kershaw, Olivia, Schlenner, Susan, Kretschmer, Karsten 05 February 2025 (has links)
Foxp3+ regulatory T (Treg) cells of thymic (tTreg) and peripheral (pTreg) developmental origin are thought to synergistically act to ensure immune homeostasis, with self-reactive tTreg cells primarily constraining autoimmune responses. Here we exploited a Foxp3-dependent reporter with thymus-specific GFP/Cre activity to selectively ablate either tTreg (ΔtTreg) or pTreg (ΔpTreg) cell development, while sparing the respective sister populations. We found that, in contrast to the tTreg cell behavior in ΔpTreg mice, pTreg cells acquired a highly activated suppressor phenotype and replenished the Treg cell pool of ΔtTreg mice on a non-autoimmune C57BL/6 background. Despite the absence of tTreg cells, pTreg cells prevented early mortality and fatal autoimmunity commonly observed in Foxp3-deficient models of complete Treg cell deficiency, and largely maintained immune tolerance even as the ΔtTreg mice aged. However, only two generations of backcrossing to the autoimmune-prone non-obese diabetic (NOD) background were sufficient to cause severe disease lethality associated with different, partially overlapping patterns of organ-specific autoimmunity. This included a particularly severe form of autoimmune diabetes characterized by an early onset and abrogation of the sex bias usually observed in the NOD mouse model of human type 1 diabetes. Genetic association studies further allowed us to define a small set of autoimmune risk loci sufficient to promote β cell autoimmunity, including genes known to impinge on Treg cell biology. Overall, these studies show an unexpectedly high functional adaptability of pTreg cells, emphasizing their important role as mediators of bystander effects to ensure self-tolerance.
|
623 |
In Vivo Expansion of Co-Transplanted T Cells Impacts on Tumor Re-Initiating Activity of Human Acute Myeloid Leukemia in NSG MiceWaskow, Claudia, von Bonin, Malte, Wermke, Martin, Nehir Cosgun, Kadriye, Thiede, Christian, Bornhauser, Martin, Wagemaker, Gerard 18 January 2016 (has links) (PDF)
Human cells from acute myeloid leukemia (AML) patients are frequently transplanted into immune-compromised mouse strains to provide an in vivo environment for studies on the biology of the disease. Since frequencies of leukemia re-initiating cells are low and a unique cell surface phenotype that includes all tumor re-initiating activity remains unknown, the underlying mechanisms leading to limitations in the xenotransplantation assay need to be understood and overcome to obtain robust engraftment of AML-containing samples. We report here that in the NSG xenotransplantation assay, the large majority of mononucleated cells from patients with AML fail to establish a reproducible myeloid engraftment despite high donor chimerism. Instead, donor-derived cells mainly consist of polyclonal disease-unrelated expanded co-transplanted human T lymphocytes that induce xenogeneic graft versus host disease and mask the engraftment of human AML in mice. Engraftment of mainly myeloid cell types can be enforced by the prevention of T cell expansion through the depletion of lymphocytes from the graft prior transplantation.
|
624 |
Development and validation of stabilized whole blood samples expressing T-cell activation markers as quality control reference materialLouw, Anne-Rika 03 1900 (has links)
Thesis (MScMed)--Stellenbosch University, 2008. / ENGLISH ABSTRACT: Introduction: Flow cytometry has progressively replaced many traditional laboratory
tests due to its greater accuracy, sensitivity and rapidity in the routine clinical settings
especially clinical trails. It is a powerful tool for the measuring of chemical (the
fluorochrome we add) and physical (size and complexity) characteristics of individual
cells. As these instruments became major diagnostic and prognostic tools, the need for
more advanced quality control, standardized procedures and proficiency testing
programs increased as these instrumentations and their methodology evolve. Minor
instrument settings can affect the reliability, reproducibility and sensitivity of the
cytometer and should be monitored and documented in order to ensure identical
conditions of measurement on a daily basis. This can be accomplished by following an
Internal Quality Assurance (IQA) and/ or External Quality Assurance (EQA) program.
Currently there are no such programs available in South Africa and poorer Africa
countries. HIV is a global concern and the laboratories and clinics in these places are in
need of such IQA programs to ensure quality of their instrumentation and accurate
patient results. Quality assurance programs such as CD Chex® and UK Nequas are
available but due to bad sample transport, leave the receiving laboratories with
nightmares. It would be best if there was a laboratory in South Africa that could
provide the surrounding laboratories with stabilized whole blood samples that can be
utilized as IQA. The transport of these samples can be more efficient due to shorter
distance and thus the temperature variations limited. Aims and Objectives: The aim of Chapter one is to familiarize the reader with general
terminology and concepts of immunology. Chapter two describes in detail the impact
stabilized whole blood had on clinical immunology concerning Quality Control and
Quality Assurance. The objective of this study is to stabilize whole blood with a shelf
life of greater than 30 days to serve as reference control material for South African
Immunophenotyping. It is further an objective to use these in-house stabilized control
samples for poorer African countries as Internal Quality Assurance reference material.
It is a still further objective to stimulate various lymphocyte subsets to express
activation antigens and then stabilize these cells for more specialized immunological
test and can serve as a QC for those required samples.
Study design: In Chapter three, the method currently used to stabilize whole blood was
modified. The stability of different concentrations of a first stabilizing agent
(Chromium Chloride hexahydrate) was investigated. Incubation periods and
concentrations of paraformaldehyde as second stabilizing agent were investigated.
Blood samples from healthy individuals (n=10) were stabilized and monitored for the
routine HIV phenotypic surface antigens over a period of 40 days. These samples
(n=10) were compared on the Becton Dickinson Biosciences (BD) FACSCalibur™
versus BD FACSCount™ instrumentation. Blood samples (n=3) were stabilized and
monitored to identify phenotypic cell surface molecules for as long as possible. They
were quantified on both flow cytrometric instruments. In addition, these stabilized
samples (n=3) were investigated as control blood for calibration purposes on the BD
FACSCount™ instrument. In Chapter four, lymphocytes were isolated and activated with various stimuli to
express sufficient activation antigens such as CD25, CD69, HLA-DR and CD40
Ligand on the T helper cell surfaces. These activated antigens were analyzed on the
BD FACSCalibur™ and further stabilized to serve as possible IQA samples in future.
Results: In Chapter three, the ten individual stabilized samples had non-significant P
values (P > 0.05) for CD3, CD4 and CD8 percentages and absolute values comparing
day 3 until day 40. Comparing the BD FACSCalibur™ versus BD FACSCount™,
resulted in a R2 = 0.9848 for CD4 absolute values and a R2 = 0.9636 for CD8 absolute
values. Stabilized blood samples (n=3) were monitored for routine HIV phenotypic
markers until day 84. The cells populations were easily identifiable and could be
quantified on both BD FACSCalibur™ and BD FACSCount™ instruments.
In Chapter four; for the activation study purposes, activated T helper lymphocytes
expressed approximately 25 to 35% CD40 Ligand cell surface molecules. The
stimulant of choice was Ionomycin at a 4μM concentration. Cells were incubated for
four hours at 37 degree Celsius in a 5% CO2 environment. For CD69 surface
expression, 6 hour incubation was optimum. The stimulus of choice in this case was
4μM Ionomycin which induced 84.21% CD69 expression in the test samples. For
CD25 expression; 6 hour incubation with PHA resulted in approximately 43% of CD25
expression. For HLA-DR surface expression; 6 hour incubation with PHA resulted in
approximately 43.32% of HLA-DR expression. Activated lymphocytes expressing
CD40 Ligand showed stability until day 23. Activated Lymphocytes expressing CD69,
CD25 and HLA-DR were stabilized in the same manner and stability could be
achieved until day 16. Conclusion: This thesis was related to the preparation of control samples (IQA)
designed to simulate whole blood having defined properties in clinical laboratory
situations. In future kits can be developed with a low, medium and high control sample
for the various immunological phenotypic determinants. Another kit can be compiled
where various activation markers can be identified, quantified with a “zero”, low and
high control. These whole blood IQA kits and “activation IQA kits” can be
implemented for training of newly qualified staff, competency testing of staff, method
development, software testing, panel settings and instrument setting testing. Control
samples ideally must have a number of properties in order to be effective. For instance
stability during storage times, preferably lasting more than a few weeks,
reproducibility and ease of handling. These will provide the information on day-to-day
variation of the technique or equipment which will enhance accuracy and improve
patient care. / AFRIKAANSE OPSOMMING: Inleiding: Vloeisitometrie tegnologie het verskeie tradisionele laboratorium toetse
vervang as gevolg van beter akuraadheid, sensitiwiteit en vinniger beskikbaarheid van
resultate in ‘n kliniese omgewing, veral kliniese proewe. Vloeisitometrie is ‘n kragtige
tegniek om chemiese (fluorokroom byvoeging) en fisiese (sel grote en kompleksiteit)
karakter eienskappe van individuele selle te meet. Met die toename in gebruik en
gewildheid van hiedie instrumente, neem die behoefde toe vir gevorderde kwaliteit
kontroles, gestandardiseerde prosedures, met profesionele toets programme tesame met
metode ontwikkeling.
Klein verstellings aan instrument parameters beinvloed die betroubaarheid,
herhaalbaarheid en sensitiwiteit van ‘n sitometer en moet gemonitor (en dokumenteer)
word om identiese kondisies van leesings op ‘n daaglikse basis te verseker. Dit kan
bereik word deur in te skakel met ‘n interne kwaliteits versekerings program [IQA:
“Internal Quality Control”] en/of ‘n eksterne kwaliteits versekerings program [EQA:
“External Quality Control”] te volg. Op die oomblik is daar geen sulke kwaliteits
versekerings programme in Suid Afrika en/of in die verarmende Afrika lande
beskikbaar nie. MIV is ‘n wêreldwye bekommernis en laboratoriums en klinieke in
hierdie gedeeltes van die land verlang ‘n dringende behoefdte vir sulke “IQA”
programme om kwaliteit van instrumentasie en akkurate pasiënt resultate te verseker
wat tot beter behandeling van pasiënte lei. Kwaliteit versekerings programme soos
“CD Chex®” en “UK Nequas” is beskikbaar, maar baie probleme met verwysing na
monster integriteit as gevolg van tydsame vervoer en aflewering kondisies word
hiermee geassosieër. Die behoefte het ontstaan vir ‘n laboratorium in Suid Afrika wat direk die omliggende
laboratoriums, hospitale en klinieke kan voorsien met gestabiliseerde blood monsters
wat gebruik kan word as “IQA”. Die vervoer en aflewerings kondisies van hierdie
monsters sal aansienlik verbeter as gevolg van die korter aflewerings afstand wat direk
die beperkte temperatuur wisseling beinvloed.
Doel van studie: Die doelwit van hoofstuk een is om vir die leser ‘n inleiding te gee
tot terminologie en konsepte van immunologie en die immune sisteem. Hoofstuk twee
beskyf die impak wat gestabiliseerde heelbloed het op die kliniese immunologie met
betrekking tot kwaliteit beheer en kwaliteit versekering. Die doelwit van hierdie studie
is om heelbloed te stabiliseer sodat die rakleeftyd meer as 30 dae is en sodoende as
verwysings-materiaal kontroles vir Suid Afrikaanse immunofenotipering kan dien. Dit
is ‘n verdere doelwit om hierdie tuis-gestabiliseerde kontrole monsters te gebruik as
“IQA” verwysings materiaal in verarmende Afrika lande. Die doelwit van hoofstuk
vier is om limfosiete te stimuleer om verskeie aktiverings merkers uit te druk op hul
selmembrane en dan te stabiliseer en dié te gebruik as Kwaliteits Kontroles vir die
meer gespesialiseerde immunologiese toetse.
Studie ontwerp: Hoofstuk drie beskryf ‘n aangepaste en verbeterde metode van heel
bloed stabiliseering. Stabiliteit word ondersoek in ‘n verskyndenheid konsentrasies van
‘n primêre stabiliseerings agent (chromium chloried heksahidraat) en inkubasie
periodes met paraformaldehied as tweede stabiliseerings agent word deeglik
gedokumenteer. Bloedmonsters van gesonde indiwidië (n=10) was gestabiliseer en
gemonitor vir roetine MIV membraanoppervlak antigene oor ‘n periode van 40 dae. Hierdie monsters (n=10) was gelees en geanaliseer op ‘n BD FACSCalibur™ en
vergelyk met ‘n BD FACSCount™ vloeisitometer instrument. Drie gestabiliseerde
heelbloed monsters (n=3) was gemonitor vir ‘n periode vir so lank moontlik die
fenotipiese selmembraan molekules identifiseerbaar was en die kwantiteit bepaalbaar
was. Hierdie drie monsters was gemeet op beide instrumente. As ‘n addisionele
doelwit, was hierdie drie gestabiliseerde monsters ondersoek om as moontlike
kalibrasie materiaal (verteenwoordig ‘n normale bloedmonster) te dien vir die BD
FACSCount™ instrument in die oggende voor pasiënt monsters gelees kan word.
In hoofstuk vier was limfosiete geϊsoleer en geaktiveer met ‘n verskyndenheid
stimulante om optimale aktiveerings-antigene uit te druk op T helper selmembrane
(byvoorbeeld CD25, CD69, HLA-DR en CD40 Ligand). Hierdie geaktiveerde
monsters was geanaliseer op die BD FACSCalibur™ en daarna gestabiliseer. Na
stabilisasie van die geaktiveerde limfosiet monsters was dit gemonitor oor ‘n tydperk
so lank moontlik data plotte leesbaar en selpopulasies identifiseerbaar was. Hierdie
monsters kan dien as ‘n moontlike “IQA” toets stel vir ‘n meer gespesialiseerde
immunologiese aktiveerings kontrole doeleindes.
Resultate: In hoofstuk drie; tien individiële gestabiliseerde heelbloed monsters het
gedui op geen-beduidende P waardes (P > 0.05) vir CD3, CD4 en CD8 persentasies en
absolute waardes; gemeet vanaf DAG 3 vergelykbaar tot-en-met DAG 40. Met korrelasie statistiek en vergelyking van die BD FACSCalibur™ met die
FACSCount™ instrumente, is die volgende opgemerk; R2 = 0.9848 vir die CD4
absolute waardes en ‘n R2 = 0.9636 vir die CD8 absolute waardes. Drie gestabiliseerde
monsters (n=3) was gemonitor vir MIV roetine fenotipeering tot en met DAG 84. Die
selpopulasies was duidelik identifiseerbaar en die kwantitatief meetbaar op albei
instrumente (BD FACSCalibur™ en BD FACSCount™).
Hoofstuk vier: geaktiveerde T helper lymphosiete het 25 – 35% membraan CD40
Ligand uitgedruk op hul selmembrane. Die stimulant van keuse was ionomysien teen
‘n optimale konsentrasie van 4μM. Die optimale inkubasie tydperk was vier ure by
37°C in 5% CO2 kondisie. Ses uur inkubasie in 4μM ionomysien by 37°C in ‘n 5%
CO2 omgewing was optimal vir die CD69 selmembraan uitdrukking en het 84.21%
opgelewer. Vir CD25 selmembraan uitdrukking was die selle vir ses ure met
phietoheamagglutinin (PHA) gestimuleer by 37°C in 5% CO2 kondisie en het 43%
CD25 selmembraan uitdrukking opgelewer. HLA-DR selmembraan uitdrukking: selle
was vir ses ure saam met PHA by 37°C in 5% CO2 kondisie inkubeer en het 43.32%
opgelewer. CD40 Ligand aktivering/gestabiliseerde limfosiete het tot en met dag 23
stabiliteit getoon. Die ligand was duidelik identifiseerbaar en kwantifiseerbaar.
Geaktiveerde lymphosiete wat CD69, CD25 en HLA-DR selmembraan merkers
uitdruk het na die stabiliseerings proses stabiliteit getoon tot-en-met dag 16. Gevolgtrekking: Die doel van hierdie studie was om verwysingskontroles voor te
berei sodat dit vars heelbloed naboots met uitkenbare eienskappe vir kliniese situasies.
‘n Toets kontrolestel met verwysings materiaal vir drie vlakke (byvoorbeeld ‘n lae,
medium en hoë kontrole) absolute selwaardes en persentasies kan voorberei word vir
roetine immunologiese fenotiperings merkers (CD3/CD4/CD8/CD45). Meer
gespesialiseerde kontrolestelle vir meer spesifieke doeleindes kan opgemaak word wat
‘n verskydenheid van limfosiet aktiveringsmerkers bevat met byvoorbeeld ‘n “nul”, lae
en hoë verwysings kontrole daarin. Hierdie heelbloed kan dien as “aktiveerde interne
kwaliteits verwysings materiaal” en kan gebruik word om nuut aangestelde
laboratorium werkers en nuut gekwalifiseerde studente op te lei. Hierdie verwysings
materiaal / kontroles kan aangewend word vir bevoegdheids doeleindes (byvoorbeeld
vir SANAS akkreditasie doeleindes), vir metode ontwikkeling, vir sagteware toetsing,
vir paneel opstelling en instrument verstellings doeleindes. Die kontroles moet ‘n
verskydenheid eienskappe bevat om effektief te wees. Byvoorbeeld, stabiliteit tydens
storing, gewenslik meer as ‘n paar weke, herhaalbaar en maklik handteerbaar. Hierdie
kontroles sal inligting voorsien op ‘n daaglikse basis tydens wisseling van tegnieke of
instrumentasie wat akuraatheid beinvloed en op die ou-end direk pasiënt versorging
bevoordeel.
|
625 |
Coreceptor expression and T lymphocyte subset distribution in HIV-infected and TB co-infected South African patients on anti-retroviral therapyNgandu, Jean Pierre Kabue 12 1900 (has links)
Thesis (MScMedSc (Pathology. Medical Virology))--University of Stellenbosch, 2009. / ENGLISH ABSTRACT: In 2007, AIDS caused an estimated 2.1 millions deaths worldwide; about 70% in sub-Saharan
Africa. HIV preferentially targets activated CD4 T cells, expressing the major HIV receptor
CD4, as well as the major chemokine coreceptors CCR5 and CXCR4. These coreceptors play
a prominent role during HIV cell entrance phase, HIV transmission and also disease
progression. They have been found to be differentially expressed by CD4 T cell subsets.
Tuberculosis coinfection may enhance immune activation in vivo thus accelerating HIV
disease progression and has become a major challenge in the control of TB in Africa.
Introduction of HAART has reduced disease progression to AIDS, as well as risk of further
morbidity and mortality. HAART results in a rapid decline of viral load and an initial increase
of peripheral CD4 count, however little is known on the effect of HAART in regulation of
coreceptor expression, immune activation status and CD4 T cell subset distribution in HIV
infection and HIV/TB coinfection.
This study is a cross-sectional analysis of coreceptor expression, immune activation status and
CD4 T cell subpopulation distribution in South African HIV and HIV/TB coinfected patients
before and after ARV. A total of 137 South African individuals were investigated, comprising
15 healthy normal donors (healthy subgroup), 10 patients with active pulmonary tuberculosis
(PTB subgroup), 33 HIV-1 positive patients without active PTB (HIV subgroup), 23 positive
patients with active PTB (HIV/PTB subgroup), 36 HIV-1 positive patients on ARV (HIV on
ARV subgroup) and 20 HIV-1 positive patients with active PTB on ARV (HIV/PTB on ARV
subgroup).
CD4 absolute count and plasma viral load were determined for all donors. Freshly isolated
PBMC were classified by flow cytometry into the following CD4+ T lymphocyte subsets:
naïve (CD45+, CD27+), effector memory (CD45-, CD27-), central memory (CD45-, CD27+),
and effector (CD45+, CD27-). Coreceptor expression and activation status was assessed by
CCR5, CXCR4 and CD38 expression on CD4 T cell subsets.
HIV, TB and HIV/TB coinfection was associated with a decrease in percentage CCR5+ T
cells as compared to healthy controls, with the HIV/TB group showing the most extensive
decrease. In treatment naive patients, CD4 T cells showed elevated surface expression of
CCR5 and CD38 as determined by mean fluorescence intensity in HIV/TB co-infection
compared to HIV infection alone. The percentage of antigen-experienced cells was higher in
the HIV/TB co-infected group compared to the HIV group. The percentage of naïve T cells
was decreased in both the HIV infected and the HIV/TB co-infected groups compared to
healthy controls. HIV patients with more than 6 months of ARV showed decreased CCR5 and
CD38 surface level expression in the HIV and the HIV/ TB co-infected subgroups. An
increased percentage of naïve T cells was observed in the HIV infected subgroup, but not in
the HIV/TB subgroup, similarly, a decreased percentage of antigen-experienced cells was
observed in the HIV subgroup, but not in the HIV/TB co-infected subgroup. A positive
correlation was found between CCR5 and CD38 expression, and CXCR4 and CD38
expression (Spearman coefficient of correlation respectively: r=0.59, p<0.001 and r=0.55,
p<0.001). Furthermore we found plasma viral load positively associated with CD38
expression (r=0.31, p<0.001) and percentage activated CCR5+ expressing CD4 T cells
positively related to viral load (r=0.31, p<0.001). Percentage naïve CD4 T cells was positively
associated with CD4 count (r=0.60, p<0.001) and negatively correlated to viral load (r=-0.42,
p<0.001).
These results indicate that TB coinfection exacerbates certain aspects of dysregulation of CD4
T cell homeostasis and activation caused by HIV infection. In addition, ARV-associated
decrease in coreceptor expression, immune activation status and a normalisation of CD4 T
cell subset distribution was observed in HIV infected individuals, but not in HIV/TB coinfection.
Despite viral suppression after ARV treatment, the decline in the immune activation
marker CD38 and coreceptor CCR5 expression, increase in percentage naïve CD4 T cells and
decrease of antigen-experienced cells did not reach the levels displayed in the healthy control
group. This may indicate that ongoing (albeit reduced) T cell immune activation may occur in
the presence of ARV. Further longitudinal studies are needed to closely monitor immune
activation during ARV treatment.
This study highlighted an association of TB disease with immune activation in HIV infection,
the importance of T-cell activation in HIV pathogenesis and its impact on ARV treatment.
Further studies are needed to identify causative factors that may lead to a persistent immune
activation status during ARV treatment, and how TB coinfection confounds normal responses
to ARV. / AFRIKAANSE OPSOMMING: In 2007 was ongeveer 2.1 miljoen sterftes wêreldwyd veroorsaak deur VIGS; ongeveer 70%
in Sub-Sahara Afrika. CD4 T selle is die hoof teiken van MIV, aangesien dit die primêre CD4
reseptor, sowel as een of beide van die vernaamste chemokien koreseptore CCR5 en CXCR4
vrystel. Hierdie koreseptore speel ‘n prominente rol wanneer die MIV die sel binnedring,
asook tydens MIV oordrag en verloop van die siekte. Dit word ook deur verskillende fraksies
van CD4 T selle vrygestel. Gelyktydige TB infeksie mag immuunaktivering in vivo verhoog
en dus die siekeproses versnel. MIV het ‘n groot uitdaging geword in die beheer van TB in
Afrika. Bekendstelling van HAART het die ontwikkeling van VIGS vertraag, asook die risiko
van verdere morbiditeit en mortaliteit. HAART veroorsaak ‘n vinnige afname in virale lading
‘n toename in CD4 telling, hoewel die spesifieke invloed van HAART op die regulering van
koreseptor vrystelling, immuunaktivering en verspreiding van CD4 fraksies in MIV en
MIV/TB infeksies nog onduidelik is.
Hierdie studie het gepoog om koreseptor vrystelling, immuunaktiveringstatus en die
verspreiding van CD4 subpopulasies in pasiënte met MIV en MIV/TB voor en na ARV
behandeling te ondersoek. ‘n Totaal van 137 Suid-Afrikaanse individue is ondersoek en die
studiegroep het bestaan uit 15 normale persone (gesonde subgroep), 10 pasiënte met aktiewe
pulmonale TB (PTB subgroup), 33 MIV positiewe pasiënte sonder PTB (MIV subgroep), 23
MIV positiewe pasiënte met aktiewe PTB (MIV/PTB subgroep), 36 MIV positiewe pasiënte
op ARV (MIV op ARV subgroep) en 20 MIV positiewe pasiënte met aktiewe PTB op ARV
(MIV/PTB op ARV subgroep).
Absolute CD4 telling en virale ladings was bepaal vir alle deelnemers. Vars geïsoleerde
perifere bloed mononukleêre selle is geklassifiseer deur middel van vloeisitometrie as die
volgende CD4 T limfosiet subgroepe: naïewe selle (CD45+, CD27+), effektor geheueselle
(CD45-, CD27-), sentrale geheueselle (CD45-, CD27+), en effektor selle (CD45+, CD27-).
Koreseptor vrystelling en aktivering was beoordeel volgens CCR5, CXCR4 en CD38
vrystelling op CD4 T sel subgroepe.
HIV, TB en MIV/TB ko-infeksie is geassosieer met ‘n afname in die persentasie CCR5+ T
selle, vergeleke met gesonde kontroles, waar die MIV/TB subgroep die grootste afname
getoon het. In onbehandelde pasiënte het die CD4 T selle verhoogde vrystelling van CCR5 en
CD38 op die oppervlakte getoon en dit is bevestig deur die gemiddelde fluoresserende
vii
intensiteit in die MIV/TB subgroep vergeleke met die subgroep met slegs MIV. Die MIV/TB
subgroep het verder ook ‘n verhoogde persentasie totale geheue T selle getoon vergeleke met
die MIV subgroep. Die persentasie naïewe T selle was egter verlaag in beide die MIV en
MIV/TB subgroepe vergeleke met normale kontroles. MIV pasiënte wat langer as 6 maande
op ARV behandeling was in beide die MIV en MIV/TB subgroepe, het ‘n verlaagde
vrystelling van CCR5 en CD38 op die oppervlakte van die CD4 selle getoon. ‘n Verhoogde
persentasie naïewe T selle het in die MIV subgroep voorgekom, maar nie in die MIV/TB
subgroup nie. ‘n Soortgelyke tendens is gevind waar die persentasie totale geheueselle
verlaag was in die MIV subgroep, maar nie in die MIV/TB subgroep nie. ‘n Positiewe
korrelasie is gevind tussen CCR5 en CD38 vrystelling, asook CXCR4 en CD38 vrystelling
(Spearman korrelasie koëffisiënt: r=0.59, p<0.001 en r=0.55, p<0.001 onderskeidelik). Verder
het die plasma virale lading ‘n positiewe assosiasie getoon met CD38 vrystelling (r=0.31,
p<0.001) en die persentasie geaktiveerde CCR5+ vrystellende CD4 T selle met virale lading
(r=0.31, p<0.001). Die persentasie naïewe CD4 T selle het ‘n positiewe assosiasie getoon met
CD4 telling (r=0.60, p<0.001) en ‘n negatiewe korrelasie met virale lading (r=-0.42,
p<0.001).
Volgens hierdie resultate vererger TB ko-infeksie sekere aspekte van die disregulasie van
CD4 T selhomeostase en aktivering as gevolg van MIV infeksie. Verder kon ‘n ARVgeassosieerde
afname in koreseptor vrystelling, immuunaktivering en normalisering van CD4
T sel fraksies bespeur word in die MIV subgroep, maar nie in die MIV/TB subgroep nie. Ten
spyte van virale onderdrukking veroorsaak deur ARV behandeling, het die afname in die
immuunmerker CD38 en koreseptor CCR5, toename in die persentasie naïewe CD4 selle en
afname in totale geheue CD4 T selle nie die vlakke van die normale kontrolegroep bereik nie.
Dit is moontlik dat volgehoue verlaagde T sel immuunaktivering nog steeds mag plaasvind in
die teenwoordigheid van ARV. Verdere longitudinale studies is nodig om immuunaktivering
tydens ARV behandeling te monitor.
Hierdie studie het die belangrikheid van T sel aktivering in MIV patogenese en dit impak
daarvan op ARV behandeling beklemtoon. Verdere studies is nodig om moontlike oorsake of
bydraende faktore te identifiseer wat tot volgehoue immuunaktivering tydens ARV
behandeling kan lei, asook tot mate waartoe TB ko-infeksie kan inmeng met die normale
werking van ARV behandeling.
|
626 |
ROLE OF OXIDATIVE STRESS AND T CELL HOMING IN THE DEVELOPMENT OF MURINE SYNGENEIC GRAFT-VERSUS-HOST DISEASEPerez-Rodriguez, Jacqueline 01 January 2009 (has links)
Syngeneic graft-versus-host disease (SGVHD) is induced by reconstituting lethally irradiated mice with syngeneic BM cells followed by a 21 day treatment with the immunosuppressive agent cyclosporine A (CsA). Clinical symptoms of the disease appear 2-3 weeks following cessation of CsA therapy and disease-associated inflammation occurs primarily in the colon and liver.
The development of SGVHD is a complex process resulting from the cooperative interaction of multiple effector cell populations including NK cells, T cells and macrophages. TH1 cytokines (IL-12, TNF-α, IFN- γ), produced by these effector cells, serve as inflammatory mediators contributing to the pathogenesis of SGVHD. The SGVHD conditioning agents, irradiation and CsA, are both required for the development of disease and contribute to the production of oxidative stress. Time course studies revealed increased reactive oxygen and nitrogen species (ROS/RNS), as well as, increased colon mRNA levels for TNF-α and iNOS in CsA-treated versus control BMT animals. Since ROS/RNS are known to mediate CsA toxicity, studies were undertaken to determine the effect of oxidative stress on the induction of SGVHD. In vivo treatment with the antioxidant MnTBAP caused a reduction in colon mRNA levels for iNOS and TNF-α, as well as delayed disease development, suggesting a role for oxidative stress in the development of SGVHD.
In addition, CD4+ T cells have been shown to play an important role in the inflammatory response observed in the gut of SGVHD mice. Time course studies revealed significant increases in the migration of CD4+ T cells as early as day 14 post- BMT into the colon of CsA mice as well as significant elevated mRNA levels of cell adhesion molecules. Homing studies revealed that a labeled CD4+ T cell line, generated from SGVHD mice, migrated in larger numbers into the gut of CsA-treated mice compared to control animals. This study demonstrated that CD4+ T cells responsible for the pathogenesis observed in murine SGVHD are present early after BMT in colons of CsA-treated mice, suggesting that during the 21 days of immunosuppression therapy functional mechanisms are in place that result in increased homing of effector cells to colons of CsA-treated mice.
|
627 |
Expression of biomarkers, representing immunosuppressive, cytotoxic or immunomodulating properties of CD8h T lymphocytes in the peripheral blood of patients with immunogenic cancer forms / Imunosupresines, citotoksines bei imunomoduliuojančias savybes atspindinčių žymenų raiška imunogeniškomis vėžio formomis sergančių ligonių periferinio kraujo CD8H T limfocitų populiacijojeStrioga, Marius 02 July 2010 (has links)
The aim of the study was to evaluate the expression of immunosuppressive (FOXP3, NKG2A), and cytotoxic (perforin) or cytotoxic / immunomodulating (IFNγ) T-cell properties representing biomarkers in the peripheral blood CD8h T-cell population of patients with advanced renal cell carcinoma (RCC) or high risk cutaneous melanoma and healthy controls by multicolour flow cytometry. Determination of the percentage of functionally competing T-cell subsets (especially immunosuppressive) in the CD8hCD57+ T-cell subpopulation in future may serve as one of parameters enabling to assess the overall status of antitumor immune response and select cancer patients most suitable for antitumor immunotherapy while dismissing those to whom it would be ineffective or even harmful. / Darbo tikslas buvo įvertinti imunosupresines (FOXP3, NKG2A), citotoksines (perforin) bei citotoksines / imunomoduliuojančias (IFNγ) savybes atspindinčių žymenų raiškos skirtumus išplitusiu inkstų vėžiu ar didelės rizikos odos melanoma sergančių pacientų periferinio kraujo CD8h T limfocitų populiacijoje, lyginant su kontroline grupe. Skirtingas T limfocitų savybes atspindinčių žymenų raiška buvo tiriama tėkmės citometrijos būdu. Nustatyta, kad inkstų vėžiu ar odos melanoma sergančių pacientų periferiniame kraujyje Įvairių subpopuliacijų (ypač imunosupresinės) nuošimčio nustatymas CD8hCD57+ T limfocitų populiacijoje ateityje gali būti naudingas klinikinėje praktikoje, individualizuojant priešnavikinę imunoterapiją ir selektyviai parenkant tik tuos pacientus, kuriems imuninės sistemos aktyvinimas sukeltų navikinių ląstelių naikinimą, o ne dar labiau gilintų imunosupresiją.
|
628 |
Imunosupresines, citotoksines bei imunomoduliuojančias savybes atspindinčių žymenų raiška imunogeniškomis vėžio formomis sergančių pacientų periferinio kraujo CD8h T limfocitų populiacijoje / Expression of biomarkers, representing immunosuppressive, cytotoxic or immunomodulating properties of Cd8h T lymphocytes in the peripheral blood of patients with immunogenic cancer formsStrioga, Marius 02 July 2010 (has links)
Darbo tikslas buvo įvertinti imunosupresines (FOXP3, NKG2A), citotoksines (perforin) bei citotoksines / imunomoduliuojančias (IFNγ) savybes atspindinčių žymenų raiškos skirtumus išplitusiu inkstų vėžiu ar didelės rizikos odos melanoma sergančių pacientų periferinio kraujo CD8h T limfocitų populiacijoje, lyginant su kontroline grupe. Skirtingas T limfocitų savybes atspindinčių žymenų raiška buvo tiriama tėkmės citometrijos būdu. Nustatyta, kad inkstų vėžiu ar odos melanoma sergančių pacientų periferiniame kraujyje Įvairių subpopuliacijų (ypač imunosupresinės) nuošimčio nustatymas CD8hCD57+ T limfocitų populiacijoje ateityje gali būti naudingas klinikinėje praktikoje, individualizuojant priešnavikinę imunoterapiją ir selektyviai parenkant tik tuos pacientus, kuriems imuninės sistemos aktyvinimas sukeltų navikinių ląstelių naikinimą, o ne dar labiau gilintų imunosupresiją. / The aim of the study was to evaluate the expression of immunosuppressive (FOXP3, NKG2A), and cytotoxic (perforin) or cytotoxic / immunomodulating (IFNγ) T-cell properties representing biomarkers in the peripheral blood CD8h T-cell population of patients with advanced renal cell carcinoma (RCC) or high risk cutaneous melanoma and healthy controls by multicolour flow cytometry. Determination of the percentage of functionally competing T-cell subsets (especially immunosuppressive) in the CD8hCD57+ T-cell subpopulation in future may serve as one of parameters enabling to assess the overall status of antitumor immune response and select cancer patients most suitable for antitumor immunotherapy while dismissing those to whom it would be ineffective or even harmful.
|
629 |
Aspects to T-cell phenotype during infection with HIV, CMV and Hepatitis C virusNorthfield, John January 2008 (has links)
This work concerns itself with understanding the organisation of cellular immune responses to three major human pathogens - HIV, CMV and Hepatitis C (HCV). Each was studied to form three projects, each undertaken with a different approach - arrived at independently - and largely owing their origins to opportunity and circumstance as much as design. Each project led to exploration of a particular aspect of T-cell phenotype (that is the expression of particular molecular markers on T-cells) and its’ broader biological significance. I found that T-cell phenotype was strongly linked to the magnitude of T-cell responses (CMV) and the ability of T-cells to control infection (HIV). Finally I explored the significance of expression of a molecule known as CD161 on the surface of HCV specific CD8+ T-cells, indicating a phenotype of T-cell that may not follow the ‘normal rules’ applicable to T-cells in general.
|
630 |
Mechanism of Inducible Costimulator (ICOS)-mediated calcium signalingLeconte, Julien 12 1900 (has links)
Le Costimulateur Inductible (ICOS) est un récepteur exprimé à la
surface des cellules T CD4 auxiliaires et T CD8 cytotoxiques. Il fut démontré
à l’aide de modèles murins de transplantation de moelle osseuse que
ICOS joue un rôle important dans l’induction de la maladie du greffon
contre l’hôte aigüe (GVHD). ICOS potentialise deux signaux médiés par le
récepteur de cellules T (TCR) : l’activation de la phosphoinositide 3-kinase
(PI3K) ainsi que la mobilisation interne de calcium. En conditions in vitro,
dans les cellules CD4 et CD8, ICOS réussi à potentialiser le flux de calcium
médié par le TCR indépendamment de PI3K. La voie de signalisation de
ICOS impliquée dans la GVHD demeure inconnue. Cependant, en
utilisant une lignée de souris ‘knock-in’ nommée ICOS-Y181F, dans laquelle
le cellules T ont sélectivement perdu la capacité d’activer PI3K par
l’entremise d’ICOS, nous avons démontré que les cellules T peuvent utiliser
un mécanisme ICOS indépendant de PI3K afin d’induire la GVHD.
La mobilisation interne du Ca2+ mène à l’activation de NFAT, un
facteur de transcription clé régulant des gènes comme IFN-γ, qui exprime
une des cytokines clés impliquées dans la GVHD. Nous émettons comme
hypothèse que la capacité pathogénique intacte des cellules T ICOSY181F
à induire la GVHD, repose sur la signalisation du Ca2+ indépendante
de PI3K. Le but de mon projet est d’identifier les résidus responsables de
cette signalisation de Ca2+ médiée par ICOS ainsi que le mécanisme par
lequel ce récepteur fonctionne. À l’aide de la mutagénèse dirigée, j’ai
généré des mutants d’ICOS et j’ai analysé par cytométrie en flux leur
capacité à activer le flux de Ca2+. J’ai ainsi identifié un groupe de lysine
sur la queue cytoplasmique d’ICOS situé à proximité de la membrane
comme étant essentiel à la fonction de potentialisation du flux de Ca2+.
Je fournis également des preuves de l’implication de la kinase Lck,
membre de la famille de kinases Src, dans la voie de signalisation de ICOS
médiant la potentialisation du flux de Ca2+. Ainsi, ICOS s’associe à Lck et
mène à une augmentation de l’activation de PLCγ1, la protéine
effectrice clé causant la sortie de Ca2+ de la réserve intracellulaire.
En conclusion, notre étude permet de comprendre davantage une
des voies de signalisation d’ICOS. L’influx de Ca2+ dans les cellules T
implique la voie ICOS-Lck-PLCγ1. Une compréhension plus approfondie de
cette voie de signalisation pourrait s’avérer bénéfique afin d’élaborer de
nouvelles stratégies menant à la prévention de maladies reliées à ICOS,
comme la GVHD. / The Inducible Costimulator (ICOS) is a receptor expressed on
activated CD4 helper and CD8 cytotoxic T cells. It was previously shown
that ICOS plays an important role in inducing acute graft versus host
disease (GVHD) in murine models of allogeneic bone marrow
transplantation (BMT). ICOS potentiates TCR-mediated phosphoinositide
3-kinase (PI3K) activation and intracellular calcium mobilization. In both
CD4+ and CD8+ T cells, ICOS can potentiate TCR-mediated calcium flux in
a PI3K-independent manner in vitro. However, the ICOS signal
transduction pathway involved in GVHD remains unknown. Using a knockin
strain of mice (termed ICOS-Y181F) in which T cells have selectively lost
the ability to activate PI3K, we have recently shown that T cells can utilize
PI3K-independent ICOS signaling pathways to induce GVHD.
The mobilization of intracellular Ca2+ leads to the activation of NFAT,
a key transcription factor regulating genes such as IFN-γ, one of the key T
cell cytokines involved in GVHD. Therefore, we hypothesize that the intact
pathogenic capacity of ICOS-Y181F T cells to induce GVHD relies on ICOSdependent,
PI3K-independent calcium signaling. My goal is to identify the
residue(s) responsible for this ICOS-mediated Ca2+ signaling and find the
mechanism by which the receptor achieves its function. Through sitedirected
mutagenesis and flow cytometric analysis of calcium fluxing
capacities of mutant ICOS proteins, I identified a membrane proximal
cluster of lysine residues that is essential in inducing ICOS-mediated Ca2+
signaling. I also provide evidence for the involvement of the Src family
kinase Lck in ICOS-mediated Ca2+signaling. ICOS associates with Lck
molecules, leading to the activation of PLCγ1, the key effector protein
causing the release of Ca2+ from the intracellular pool.
Taken together, our study is beginning to unravel a complexity in
ICOS signaling, and implicates the ICOS-Lck-PLCγ1 axis in T cell calcium
signaling and potentially the induction of GVHD. Further understanding of
this pathway could prove beneficial in designing new strategies to
prevent ICOS-related diseases such as GVHD.
|
Page generated in 0.0669 seconds